Gastrointestinal Bleeding: a Cardiologist's Point of View
Open Access
- 3 November 2021
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (5), 771-778
- https://doi.org/10.20996/1819-6446-2021-10-01
Abstract
Oral anticoagulant therapy is widely used in different patients for the prevention and treatment of thromboembolic events: in atrial fibrillation, deep vein thrombosis/pulmonary embolism, acute coronary syndrome, in the early postoperative period after orthopedic surgery. Nowadays it is possible to use vitamin K antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban and edoxaban. The mai complication of any anticoagulant therapy is bleeding (gastrointestinal, intracranial, etc.), which seriously limits its usage. In this review the incidence of gastrointestinal bleeding (GIB) associated with oral anticoagulants intake was analyzed according to the results of both large randomized and postregistration trials. Furthermore, the effect of age on the risk of GIB development is discussed, and also aspects of the pathophysiology of gastrointestinal mucosa lesions in patients taking DOAC are considered.Keywords
This publication has 43 references indexed in Scilit:
- Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxabanBritish Journal of Haematology, 2013
- New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysisGastroenterology, 2013
- Dabigatran and Postmarketing Reports of BleedingThe New England Journal of Medicine, 2013
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategiesThrombosis and Haemostasis, 2013
- Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2012
- Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial FibrillationJournal of Invasive Cardiology, 2012
- Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillationInternational Journal of Clinical Practice, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009